Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 21
Filtrar
Más filtros

País/Región como asunto
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Indian J Endocrinol Metab ; 24(5): 402-405, 2020.
Artículo en Inglés | MEDLINE | ID: mdl-33489844

RESUMEN

INTRODUCTION: Acromegaly is associated with high morbidity, but still controversial impact on the overall quality of life (QoL). MATERIAL AND METHODS: We evaluated QoL using a generic (SF-36) and a disease-specific questionnaire (AcroQoL) in an acromegalic cohort. RESULTS: Sixty-nine patients answered the questionnaires and had their records reviewed. In the SF-36 questionnaire, except for the Social Aspects domain, all others revealed a reduction in scores from 9.7 to 38.9%, when compared to the non-acromegalics. The cure was positively correlated with mental health (P = 0.023) and drug control was correlated with mental health (P = 0.023) and functional capacity (P = 0.013). In the AcroQoL questionnaire, the mean scores ranged from 54.7% to 72.8%. The use of antidepressants correlated with lower scores on the total AcroQoL (P = 0.039) and physical complaints (P = 0.003). The growth hormone value at diagnosis showed an inverse correlation with the total AcroQoL score (P = 0.014), Appearance Issues subscale (P = 0.081), and Personal Relations (P = 0.002). IGF-1 values at diagnosis and at the last visit showed no statistical correlation with any of the questionnaires. CONCLUSION: The finding of a reduction in QoL scores with both SF-36 and AcroQoL allows us to suggest this evaluation as part of the initial assessment and follow-up in acromegaly, to act globally on the individual's health condition.

2.
Indian J Endocrinol Metab ; 23(4): 473-479, 2019.
Artículo en Inglés | MEDLINE | ID: mdl-31741909

RESUMEN

INTRODUCTION: Individuals with pituitary adenomas may have organic consequences of their disease or therapy, and psychological changes can compromise their quality of life (QoL). This study aimed to determine the anthropometric profile and health indicators of patients with pituitary adenoma before and after pituitary surgery. METHODS: Forty-four patients were included in this study. Out of these, 22 patients had nonfunctioning adenomas (50%), 17 acromegaly (38.6%), and 5 patients with Cushing's disease (11.4%). Anthropometric measurements included body mass index (BMI), waist circumference (WC), and waist-to-hip ratio (WHR). Health indicators included body fat percentage (BF%), basal metabolic rate (BMR), maximal oxygen uptake (VO2 max), and hand grip strength. Physical activity level (the International Physical Activity Questionnaire [IPAQ]), subjective perception of health, body image (Body Shape Questionnaire), body satisfaction (Stunkard Figure Rating Scale) were used. RESULTS: The mean patient age was 47.2 ± 14.6 years; of which 25 were women (56.8%). Before surgery, 75.0% were overweight or obese, 84.1% had WC with risk of metabolic complications, and 90.0% had WHR with cardiovascular risk. There was a high BF% in 56.4% of cases, low BMR in 65.1%, lower VO2 max in 16.2%, and below-average grip strength in 88.6%. Hypopituitary patients had poorer cardiorespiratory fitness. The IPAQ showed reduction in physical activity, and 79.5% of patients were dissatisfied with their body image. Patients with nonfunctioning adenomas had better perception of their health while those with Cushing's disease had more distorted body image. Postoperatively, patients with acromegaly showed improvement in WHR and physical activity level, and patients with Cushing's disease showed improvement in anthropometric variables. CONCLUSIONS: These findings emphasize the need for continuous monitoring of this population for anthropometric indicators associated with metabolic and cardiovascular comorbidities as well as body satisfaction.

3.
Arq Neuropsiquiatr ; 77(8): 536-541, 2019 09 05.
Artículo en Inglés | MEDLINE | ID: mdl-31508678

RESUMEN

OBJECTIVE: To study the impact of surgery on pain, disability, quality of life, and patient satisfaction in a sample of patients with Degenerative Lumbar Disease (DLD). METHODS: Retrospective analysis of prospectively collected data. Comparison between pre and postoperative (6 - 12 months) ODI and SF-36, plus postoperative Patient Satisfaction Index. RESULTS: From a total of 216 patients included, improvement was observed in average scores of pain (201.2%), disability (39.7%), physical quality of life (42%), and mental quality of life (37.8%). Among these patients, 57.7% reached or surpassed the minimal clinically important difference (MCID) for ODI, 57.7% for the SF-36 pain component, 59.7% for the SF-36 physical component summary, and 50.5% achieved or surpassed the MCID for the SF-36 mental component summary. CONCLUSIONS: Surgery produced a significantly positive impact on pain, disability, and quality of life of patients. Overall, 82.5% of the patients were satisfied.


Asunto(s)
Evaluación de la Discapacidad , Degeneración del Disco Intervertebral/fisiopatología , Degeneración del Disco Intervertebral/cirugía , Vértebras Lumbares/fisiopatología , Vértebras Lumbares/cirugía , Calidad de Vida , Adulto , Anciano , Brasil , Femenino , Humanos , Masculino , Persona de Mediana Edad , Dimensión del Dolor , Satisfacción del Paciente , Estudios Retrospectivos , Encuestas y Cuestionarios , Resultado del Tratamiento
4.
Arq. neuropsiquiatr ; 77(8): 536-541, Aug. 2019. tab, graf
Artículo en Inglés | LILACS | ID: biblio-1019469

RESUMEN

ABSTRACT Objective: To study the impact of surgery on pain, disability, quality of life, and patient satisfaction in a sample of patients with Degenerative Lumbar Disease (DLD). Methods: Retrospective analysis of prospectively collected data. Comparison between pre and postoperative (6 - 12 months) ODI and SF-36, plus postoperative Patient Satisfaction Index. Results: From a total of 216 patients included, improvement was observed in average scores of pain (201.2%), disability (39.7%), physical quality of life (42%), and mental quality of life (37.8%). Among these patients, 57.7% reached or surpassed the minimal clinically important difference (MCID) for ODI, 57.7% for the SF-36 pain component, 59.7% for the SF-36 physical component summary, and 50.5% achieved or surpassed the MCID for the SF-36 mental component summary. Conclusions: Surgery produced a significantly positive impact on pain, disability, and quality of life of patients. Overall, 82.5% of the patients were satisfied.


RESUMO Objetivo: Descrever o impacto da cirurgia na dor, incapacidade, qualidade de vida e a satisfação global do paciente numa amostra unificada de pacientes portadores de DDL. Métodos: Análise retrospectiva de dados colhidos prospectivamente em pacientes operados no período de janeiro de 2014 a março de 2017, que tivessem avaliação pré-operatória e pelo menos uma avaliação pós-operatória entre 6 e 12 meses com os questionários de ODI, SF-36 e o ISP. Resultados: Um total 216 pacientes preenchia os critérios de inclusão. Houve melhora no escore médio de dor (201,2%), incapacidade (39,7%), qualidade de vida física (42%) e mental (37,8%). Da amostra, 57,7% alcançaram o MCID de dor, 59,7% de ODI, 59,7% 50,5% de PCS e 50,5% de MCS; 82,5% dos pacientes se consideraram "Satisfeitos". Conclusões: O efeito da cirurgia foi amplamente favorável na dor, incapacidade e qualidade de vida dos pacientes portadores de DDL. Estes dados podem servir de guia para aconselhamento pré-operatório quanto às perspectivas de sucesso.


Asunto(s)
Humanos , Masculino , Femenino , Adulto , Persona de Mediana Edad , Anciano , Calidad de Vida , Evaluación de la Discapacidad , Degeneración del Disco Intervertebral/cirugía , Degeneración del Disco Intervertebral/fisiopatología , Vértebras Lumbares/cirugía , Vértebras Lumbares/fisiopatología , Dimensión del Dolor , Brasil , Encuestas y Cuestionarios , Estudios Retrospectivos , Resultado del Tratamiento , Satisfacción del Paciente
5.
Clin Endocrinol (Oxf) ; 80(3): 411-8, 2014 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-23895112

RESUMEN

OBJECTIVE: To evaluate the ability of post-transsphenoidal pituitary surgery (TSS) serum cortisol levels (s-cortisol) to predict surgical remission and recurrence of Cushing's disease (CD). DESIGN: One hundred and three patients with CD from a tertiary referral centre were prospectively analysed over 6·0 ± 4·8 years of follow-up. Twenty patients received perioperative glucocorticoids as routine care and had s-cortisol measured 10-12 days after TSS (Protocol I). Eighty-six patients (91 surgeries) had s-cortisol measured at 6, 12, 18, 24, 48 h, and 10-12 days after TSS, and received glucocorticoids only in case of adrenal insufficiency (Protocol II). MAIN OUTCOMES: Remission [clinical signs and symptoms of adrenal insufficiency (or hypocortisolism) plus cortisol <3 µg/dl on the 1-mg overnight test (OT) and/or normal free urinary cortisol] during follow-up. Recurrence was defined as loss of remission criteria at least 1 year after TSS. RESULTS: The remission rate after first TSS was 80%; 8% had recurrence. An s-cortisol nadir ≤3·5 µg/dl within 48 h after TSS had sensitivity of 73%, specificity and positive predictive value (PPV) of 100% and negative predictive value (NPV) of 60% and an s-cortisol nadir ≤5·7 µg/dl within 10-12 days of TSS had specificity and PPV of 100% and sensitivity of 91% NPV of 78% for CD remission. CONCLUSION: At hospital discharge, the s-cortisol nadir within 48 h after TSS was already able to predict surgical remission for some patients, and the s-cortisol nadir within 10-12 days of TSS was able to predict cohort-wide surgical remission.


Asunto(s)
Hidrocortisona/sangre , Procedimientos Neuroquirúrgicos/métodos , Hipersecreción de la Hormona Adrenocorticotrópica Pituitaria (HACT)/diagnóstico , Hipersecreción de la Hormona Adrenocorticotrópica Pituitaria (HACT)/cirugía , Adolescente , Adulto , Niño , Estudios de Cohortes , Femenino , Estudios de Seguimiento , Humanos , Masculino , Persona de Mediana Edad , Alta del Paciente , Hipersecreción de la Hormona Adrenocorticotrópica Pituitaria (HACT)/sangre , Valor Predictivo de las Pruebas , Recurrencia , Inducción de Remisión , Seno Esfenoidal/cirugía , Resultado del Tratamiento , Adulto Joven
6.
Arq Bras Endocrinol Metabol ; 55(4): 284-7, 2011 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-21779632

RESUMEN

Benign intracranial hypertension (Pseudotumor cerebri) has been described as related to the reduction in steroid levels in Cushing's disease (CD), especially after surgical remission. Ketoconazole is a common and effective adjuvant therapy for hypercortisolism, but the major concern is liver enzyme dysfunction. We describe here the case of a 12-year old girl with CD who developed benign intracranial hypertension during treatment with ketoconazole. She presented headache, vomiting, a black spot on her right temporal visual field, and signs of elevated intracranial pressure. Pituitary image was normal on magnetic resonance image (MRI), and all symptoms improved after treatment with acetazolamide. We call attention to the diagnosis of this disorder in CD patients, especially children on ketoconazole treatment, because it could be confounded with adrenal insufficiency and lead to definitive severe visual impairment.


Asunto(s)
Cetoconazol/efectos adversos , Hipersecreción de la Hormona Adrenocorticotrópica Pituitaria (HACT)/tratamiento farmacológico , Seudotumor Cerebral/inducido químicamente , Insuficiencia Suprarrenal/diagnóstico , Niño , Diagnóstico Diferencial , Femenino , Humanos , Seudotumor Cerebral/diagnóstico
7.
Arq. bras. endocrinol. metab ; 55(4): 284-287, June 2011. ilus, tab
Artículo en Inglés | LILACS | ID: lil-593122

RESUMEN

Benign intracranial hypertension (Pseudotumor cerebri) has been described as related to the reduction in steroid levels in Cushing's disease (CD), especially after surgical remission. Ketoconazole is a common and effective adjuvant therapy for hypercortisolism, but the major concern is liver enzyme dysfunction. We describe here the case of a 12-year old girl with CD who developed benign intracranial hypertension during treatment with ketoconazole. She presented headache, vomiting, a black spot on her right temporal visual field, and signs of elevated intracranial pressure. Pituitary image was normal on magnetic resonance image (MRI), and all symptoms improved after treatment with acetazolamide. We call attention to the diagnosis of this disorder in CD patients, especially children on ketoconazole treatment, because it could be confounded with adrenal insufficiency and lead to definitive severe visual impairment.


Hipertensão intracraniana benigna (Pseudotumor cerebral) tem sido descrita relacionada à redução dos níveis de esteroides séricos na doença de Cushing (DC), especialmente após a remissão cirúrgica. O cetoconazol é uma opção efetiva e de uso rotineiro como adjuvante na terapêutica do hipercortisolismo, tendo como paraefeito mais temido a toxicidade hepática. Relatamos o caso de uma menina com 12 anos de idade portadora de DC que desenvolveu hipertensão intracraniana benigna durante tratamento com cetoconazol. Apresentou-se com cefaleia, vômitos, comprometimento do campo visual temporal direito e sinais de hipertensão intracraniana. A ressonância magnética (RM) de hipófise era normal e todos os sinais e sintomas resolveram-se com uso de acetazolamida. Chamamos a atenção para esse diagnóstico nos pacientes com DC, especialmente crianças, em tratamento com cetoconazol, porque ele pode ser confundido com insuficiência adrenal e causar comprometimento visual severo e definitivo.


Asunto(s)
Niño , Femenino , Humanos , Cetoconazol/efectos adversos , Hipersecreción de la Hormona Adrenocorticotrópica Pituitaria (HACT)/tratamiento farmacológico , Seudotumor Cerebral/inducido químicamente , Insuficiencia Suprarrenal/diagnóstico , Diagnóstico Diferencial , Seudotumor Cerebral/diagnóstico
8.
Surg Neurol Int ; 1: 91, 2010 Dec 22.
Artículo en Inglés | MEDLINE | ID: mdl-21206899

RESUMEN

BACKGROUND: As a consequence of the progressive evolution of neurosurgical techniques, there has been increasing concern with the esthetic aspects of burr holes. Therefore, the objective of this study was to compare the use of cortical bone graft and bone dust for correcting cranial deformities caused by neurosurgical trephines. METHODS: Twenty-three patients were enrolled for cranial burr hole reconstruction with a 1-year follow-up. A total of 108 burr holes were treated; 36 burr holes were reconstructed with autogenous cortical bone discs (33.3%), and the remaining 72 with autogenous wet bone powder (66.6%). A trephine was specifically designed to produce this coin-shaped bone plug of 14 mm in diameter, which fit perfectly over the burr holes. The reconstructions were studied 12 months after the surgical procedure, using three-dimensional quantitative computed tomography. Additionally, general and plastic surgeons blinded for the study evaluated the cosmetic results of those areas, attributing scores from 0 to 10. RESULTS: The mean bone densities were 987.95 ± 186.83 Hounsfield units (HU) for bone fragment and 473.55 ± 220.34 HU for bone dust (P < 0.001); the mean cosmetic scores were 9.5 for bone fragment and 5.7 for bone dust (P < 0.001). CONCLUSIONS: The use of autologous bone discs showed better results than bone dust for the reconstruction of cranial burr holes because of their lower degree of bone resorption and, consequently, better cosmetic results. The lack of donor site morbidity associated with procedural low cost qualifies the cortical autograft as the first choice for correcting cranial defects created by neurosurgical trephines.

11.
Neuropathology ; 29(1): 40-4, 2009 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-18673444

RESUMEN

Angiogenesis, a fundamental process for the development and growth of a tumor, is less expressive in adenomas than in the normal pituitary tissue. There is controversy about the behavior of angiogenesis as a function of hormonal secretion or other characteristics of pituitary tumors. Endoglin (CD105) is a proliferation-associated antigen on endothelial cells, as well as an endothelial progenitor cell marker. We used the anti-endoglin antibody, a glycoprotein expressed in endothelial cells and conjunctive tissue, as a new marker particularly associated with neovascularization, in order to determine microvascular density (MVD) in pituitary adenomas. There were 77 samples, 31 males and 46 females, carriers of micro- (n = 24) or macroadenomas (n = 53). No significant difference was found in MVD concerning the variables of age, clinical presentation, and immunohistochemical phenotype or tumor size. MVD in males (median 5.4) was significantly higher (P = 0.001) than in females (median 3.0). Cell proliferation, as evaluated by the MIB-1 antibody (a cellular proliferation index [Ki-67 antigen], which is present in all stages of the cellular cycle except for the resting cells), ranged from 0% to 19.58%. No correlation was found between MIB-1 and MVD. It is possible to infer that the lower MVD found in pituitary adenomas in females reflects an inhibitory estrogen action on TGF-beta1, a protein involved in vascular remodeling. Because of its role as a TGF receptor ligand, endoglin proved to be sensitive in detecting this gender difference in pituitary tumor angiogenesis.


Asunto(s)
Adenoma/patología , Antígenos CD/análisis , Neovascularización Patológica/patología , Neoplasias Hipofisarias/patología , Receptores de Superficie Celular/análisis , Adenoma/metabolismo , Adulto , Envejecimiento , Análisis de Varianza , Anticuerpos , Anticuerpos Antinucleares , Anticuerpos Monoclonales , Antígenos CD/inmunología , Proliferación Celular , Endoglina , Femenino , Humanos , Inmunohistoquímica , Masculino , Microvasos/metabolismo , Microvasos/patología , Persona de Mediana Edad , Neovascularización Patológica/metabolismo , Hormonas Hipofisarias/metabolismo , Neoplasias Hipofisarias/metabolismo , Receptores de Superficie Celular/inmunología , Caracteres Sexuales , Carga Tumoral
12.
Arq. bras. endocrinol. metab ; 51(8): 1362-1372, nov. 2007. ilus, tab
Artículo en Inglés | LILACS | ID: lil-471753

RESUMEN

We review the clinical and biochemical criteria used for evaluation of the transsphenoidal pituitary surgery results in the treatment of Cushing's disease (CD). Firstly, we discuss the pathophysiology of the hypothalamic-pituitary-adrenal axis in normal subjects and patients with CD. Considering the series published in the last 25 years, we observed a significant variation in the remission or cure criteria, including the choice of biochemical tests, timing, threshold values to define remission, and the interference of glucocorticoid replacement or previous treatment. In this context we emphasize serum cortisol levels obtained early (from hours to 12 days) in the postoperative period without any glucocorticoid replacement or treatment. Our experience demonstrates that: (i) early cortisol < 5 to 7 µg/dl, (ii) a period of glucocorticoid dependence > 6 mo, (iii) absence of response of cortisol/ACTH to CRH or DDAVP, (iv) return of dexamethasone suppression, and circadian rhythm of cortisol are appropriate indices of remission of CD. In patients with undetectable cortisol levels early after surgery, recurrence seems to be low. Finally, although certain biochemical patterns are more suggestive of remission or surgical failure, none has been proven to be completely accurate, with recurrence observed in approximately 10 to 15 percent of the patients in long-term follow-up. We recommended that patients with CD should have long-term monitoring of the CRH-ACTH-cortisol axis and associated co-morbidities, especially hypopituitarism, diabetes mellitus, hypertension, cardiovascular disturbances, and osteoporosis.


Neste artigo, são revisados os principais critérios clínicos e hormonais utilizados para avaliação do tratamento cirúrgico da Doença de Cushing (DC). Inicialmente são comentados aspectos fisiopatológicos que orientam a avaliação hormonal e os principais fatores clínicos, laboratoriais, cirúrgicos e histológicos associados com melhores resultados, observados nas principais séries da literatura e em pacientes acompanhados prospectivamente pelos autores. Foram revisados, também, critérios adotados nas principais séries da literatura, nos últimos 25 anos, chamando-se atenção para as dosagens hormonais, o momento em que foram realizadas, a possibilidade de interferência de tratamentos prévios e da reposição glicocorticóide. À seguir, essas dosagens são discutidas salientando-se a importância do cortisol obtido seqüencialmente no pós-operatório e sem a interferência de reposição glicocorticóide. A experiência prospectiva dos autores, recentemente referendada na literatura, demonstra que valores de cortisol < 5 a 7 µg/dl associados com um período de dependência aos glicocorticóides > 6 meses, ausência de resposta do ACTH/cortisol ao DDAVP e/ou CRH, retorno da supressão à dexametasona e do ritmo circadiano, estão associados com remissão da DC. Em pacientes com cortisol indetectável após cirurgia transesfenoidal, a chance de recidiva parece ser menor do que naqueles em que se observa cortisol detectável. Finalmente, chamamos a atenção para que, mesmo adotando critérios rígidos de avaliação, a recidiva da DC pode ocorrer a longo prazo em até 15 por cento dos casos, recomendando-se, portanto, que esses pacientes sejam acompanhados por tempo indeterminado, com monitorização cuidadosa do eixo CRH-ACTH-cortisol e de suas co-morbidades, especialmente hipopituitarismo, diabete melito, hipertensão arterial, alterações cardiovasculares e osteoporose.


Asunto(s)
Humanos , Adenoma Hipofisario Secretor de ACTH , Adenoma , Hipersecreción de la Hormona Adrenocorticotrópica Pituitaria (HACT) , Neoplasias Hipofisarias , Adenoma Hipofisario Secretor de ACTH/fisiopatología , Adenoma Hipofisario Secretor de ACTH/cirugía , Adenoma/fisiopatología , Adenoma/cirugía , Hormona Adrenocorticotrópica/sangre , Hormona Liberadora de Corticotropina/sangre , Hipofisectomía , Hidrocortisona/sangre , Hidrocortisona/orina , Sistema Hipotálamo-Hipofisario/fisiopatología , Pruebas de Función Adreno-Hipofisaria , Hipersecreción de la Hormona Adrenocorticotrópica Pituitaria (HACT)/fisiopatología , Hipersecreción de la Hormona Adrenocorticotrópica Pituitaria (HACT)/cirugía , Neoplasias Hipofisarias/fisiopatología , Neoplasias Hipofisarias/cirugía , Sistema Hipófiso-Suprarrenal/fisiopatología , Recurrencia , Resultado del Tratamiento
13.
Arq Bras Endocrinol Metabol ; 51(8): 1362-72, 2007 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-18209875

RESUMEN

We review the clinical and biochemical criteria used for evaluation of the transsphenoidal pituitary surgery results in the treatment of Cushing's disease (CD). Firstly, we discuss the pathophysiology of the hypothalamic-pituitary-adrenal axis in normal subjects and patients with CD. Considering the series published in the last 25 years, we observed a significant variation in the remission or cure criteria, including the choice of biochemical tests, timing, threshold values to define remission, and the interference of glucocorticoid replacement or previous treatment. In this context we emphasize serum cortisol levels obtained early (from hours to 12 days) in the postoperative period without any glucocorticoid replacement or treatment. Our experience demonstrates that: (i) early cortisol < 5 to 7 microg/dl, (ii) a period of glucocorticoid dependence > 6 mo, (iii) absence of response of cortisol/ACTH to CRH or DDAVP, (iv) return of dexamethasone suppression, and circadian rhythm of cortisol are appropriate indices of remission of CD. In patients with undetectable cortisol levels early after surgery, recurrence seems to be low. Finally, although certain biochemical patterns are more suggestive of remission or surgical failure, none has been proven to be completely accurate, with recurrence observed in approximately 10 to 15% of the patients in long-term follow-up. We recommended that patients with CD should have long-term monitoring of the CRH-ACTH-cortisol axis and associated co-morbidities, especially hypopituitarism, diabetes mellitus, hypertension, cardiovascular disturbances, and osteoporosis.


Asunto(s)
Adenoma Hipofisario Secretor de ACTH , Adenoma , Hipersecreción de la Hormona Adrenocorticotrópica Pituitaria (HACT) , Neoplasias Hipofisarias , Adenoma Hipofisario Secretor de ACTH/fisiopatología , Adenoma Hipofisario Secretor de ACTH/cirugía , Adenoma/fisiopatología , Adenoma/cirugía , Hormona Adrenocorticotrópica/sangre , Hormona Liberadora de Corticotropina/sangre , Humanos , Hidrocortisona/sangre , Hidrocortisona/orina , Hipofisectomía , Sistema Hipotálamo-Hipofisario/fisiopatología , Hipersecreción de la Hormona Adrenocorticotrópica Pituitaria (HACT)/fisiopatología , Hipersecreción de la Hormona Adrenocorticotrópica Pituitaria (HACT)/cirugía , Neoplasias Hipofisarias/fisiopatología , Neoplasias Hipofisarias/cirugía , Pruebas de Función Adreno-Hipofisaria , Sistema Hipófiso-Suprarrenal/fisiopatología , Recurrencia , Resultado del Tratamiento
14.
Arq. bras. endocrinol. metab ; 49(5): 674-690, out. 2005. ilus, tab
Artículo en Portugués | LILACS | ID: lil-419969

RESUMEN

A hipófise, a sela túrcica e a região peri-selar podem ser acometidas por uma série de lesões, incluindo tumores benignos e malignos, bem como uma ampla variedade de doenças não neoplásicas. Os aspectos clínicos e radiológicos podem auxiliar no diagnóstico diferencial destas lesões. Porém, em muitos casos, somente a análise histopatológica pode estabelecer o diagnóstico definitivo. Neste artigo, revisamos principais tumores não hipofisários da região selar e peri-selar, ressaltando seus aspectos endócrinos mais relevantes.


Asunto(s)
Humanos , Silla Turca , Neoplasias Craneales/diagnóstico , Diagnóstico Diferencial , Imagen por Resonancia Magnética , Neoplasias Craneales/clasificación , Tomografía Computarizada por Rayos X
15.
Endocr Pathol ; 16(4): 355-62, 2005.
Artículo en Inglés | MEDLINE | ID: mdl-16627922

RESUMEN

Craniopharyngiomas are benign tumors of the sellar region generally associated with endocrine abnormality and often locally aggressive. Several studies have demonstrated that angiogenesis or neovascularization plays an important role in tumoral growth. The microvascular density (MVD) of craniopharyngiomas was determined in tumor tissue samples from a reference neurosurgery center located in southern Brazil using immunohistochemical methods for two endothelial markers, CD34 and CD105 (endoglin). In addition, tissue expression was determined for an angiogenesis stimulatory factor and for one of its inhibitors, the vascular endothelial growth factor (VEGF) and endostatin, respectively. Endothelial cell immunoreactivity for CD34 and CD105 was observed scattered within the stroma. MVD determined using CD105 antigen was significantly lower than the results obtained by using CD34 antigen. There was no association between the two endothelial markers and tumor extension. The epithelial component showed different degrees of immunoreactivity for VEGF and endostatin in all samples analyzed. We were not able to establish a relationship between angiogenesis in craniopharyngiomas and tumor extension with the endothelial markers used in this study. The investigated vascularization stimulatory and inhibitory factors showed no relation with MVD. We believe that CD105 antigen can be a more specific endothelial marker for tumor angiogenesis than CD34 antigen.


Asunto(s)
Craneofaringioma/irrigación sanguínea , Endostatinas/metabolismo , Neovascularización Patológica/patología , Neoplasias Hipofisarias/irrigación sanguínea , Factor A de Crecimiento Endotelial Vascular/metabolismo , Adolescente , Adulto , Antígenos CD/metabolismo , Antígenos CD34/metabolismo , Niño , Craneofaringioma/metabolismo , Craneofaringioma/patología , Endoglina , Endotelio Vascular/metabolismo , Femenino , Humanos , Inmunohistoquímica , Masculino , Persona de Mediana Edad , Neoplasias Hipofisarias/metabolismo , Neoplasias Hipofisarias/patología , Receptores de Superficie Celular/metabolismo
16.
Arq Bras Endocrinol Metabol ; 49(5): 674-90, 2005 Oct.
Artículo en Portugués | MEDLINE | ID: mdl-16444350

RESUMEN

The pituitary gland, sella turcica and the parasellar region can be involved by a wide variety of lesions, including benign and malignant neoplasms as well as a wide variety of non neoplastic tumor-like lesions. Clinical and radiological aspects could help in the differential diagnosis of these lesions. Nevertheless, in many cases only the histopathological analysis could establish the definitive diagnosis. In this paper, we review the nonpituitary tumors of the sellar region emphasizing the associated hormonal disturbances.


Asunto(s)
Silla Turca , Neoplasias Craneales/diagnóstico , Diagnóstico Diferencial , Humanos , Imagen por Resonancia Magnética , Neoplasias Craneales/clasificación , Tomografía Computarizada por Rayos X
17.
Neuroendocrinology ; 79(3): 119-24, 2004 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-15103224

RESUMEN

With the aim of evaluating the relationship between pituitary tumorigenesis and the presence of estrogen receptor-alpha (ERalpha) by immunohistochemistry (IH) and their relevance to patients' clinical presentation, hormonal phenotypes of adenomas, preoperative neuroimaging findings, and the index of cellular replication MIB-1, a study was conducted with material from 91 women and 67 men with pituitary adenomas. The patients had acromegaly (29.7%), Cushing's disease (14.6%), hyperprolactinemic syndrome (20.9%), and clinically nonfunctioning tumors (34.8%). Of the patients, 14.6% had microadenomas, 52.5% had macroadenomas with or without suprasellar growth, 28.5% had invasive macroadenomas and in 4.4% the adenoma was not visualized. IH showed that 43 were positive for growth hormone (GH), 16 for corticotropin (ACTH), 18 for prolactin (PRL), 18 for PRL+GH, 6 for luteinizing hormone (LH) and follicle-stimulating hormone (FSH), 15 had a plurihormonal reaction, and 42 had nonfunctioning adenomas. The presence of ERalpha was positive in 9/158 adenomas with a median value for the percentage of labeled cells of 42.89%, and in 6/16 controls (autopsy samples) with a median value for the percentage of labeled cells of 0.024%. ERalpha was significantly more prevalent in controls than in patients with adenomas (37.5 versus 5.7%; p = 0.001); however, the mean ERalpha concentration in adenomas was significantly greater than in controls (42.89 versus 0.024%; p < 0.001). No significant difference in the concentration of ERalpha was found across the clinical presentations, hormonal phenotypes or findings of preoperative CT. Among the ERalpha-positive adenomas, ERalpha values were significantly greater in invasive macroadenomas (80%) than in microadenomas (3.33%). MIB-1 values did not differ significantly between ERalpha-positive and -negative adenomas, nor did the correlation between ERalpha values and the MIB-1 index attain significance in the total sample, even when only ERalpha-positive adenomas and positive MIB-1 indexes were considered. It was concluded that, when present in pituitary tumors, ERalpha exhibits a high concentration, and is more common in nonfunctioning and invasive adenomas, but absent in ACTH-secreting ones.


Asunto(s)
Adenoma/clasificación , Adenoma/metabolismo , Antígeno Ki-67/metabolismo , Neoplasias Hipofisarias/clasificación , Neoplasias Hipofisarias/metabolismo , Receptores de Estrógenos/metabolismo , Adenoma/patología , Adulto , División Celular , Estudios Transversales , Receptor alfa de Estrógeno , Femenino , Humanos , Inmunohistoquímica , Masculino , Persona de Mediana Edad , Neoplasias Hipofisarias/patología , Estudios Retrospectivos
18.
Rev. AMRIGS ; 41(1): 41-7, jan.-mar. 1997.
Artículo en Portugués | LILACS | ID: lil-194042

RESUMEN

O diurético osmótico manitol é uma droga amplamente utilizada em neurociruriga e neurologia a fim de diminuir a pressäo intracraniana e melhorar a microcirculaçäo cerebral. As teorias sobre seu mecanismo de açäo säo revisadas: gradiente osmótico pela barreira hematoencefálica, auto-regulaçäo vascular e neutralizaçäo dos radicais livres do oxigênio. Sua posologia é empírica, segunda a experiência própria de cada autor. O conhecimento dos critérios básicos para o uso do manitol e de sua reposiçäo hidreletrolítica é fundamental para a manutençäo da osmolaridade sérica em valores terapêuticos


Asunto(s)
Manitol/administración & dosificación , Manitol/farmacología , Diuréticos Osmóticos/administración & dosificación , Diuréticos Osmóticos/farmacología , Seudotumor Cerebral/tratamiento farmacológico
19.
Arq. neuropsiquiatr ; 52(1): 58-63, mar. 1994. ilus, graf
Artículo en Inglés | LILACS | ID: lil-129366

RESUMEN

Säo estudados dois pacientes com lipoma no ângulo pontocerebelar (APC), submetidos a tratamento cirúrgico. A literatura disponível foi revisada, tendo sido identificados 29 casos submetidos a tratamento cirúrgico, com a mesma lesäo. As manifestaçöes clínicas, possibilidades dos métodos diagnósticos, indicaçöes cirúrgicas e estratégias operatórias säo discutidas. Chama-se a atençäo para as peculiaridades dos lipomas do APC e as discutível validade da tentativa de remoçäo completa em todos os casos


Asunto(s)
Humanos , Masculino , Femenino , Adulto , Persona de Mediana Edad , Ángulo Pontocerebeloso/cirugía , Neoplasias Cerebelosas/cirugía , Lipoma/cirugía , Ángulo Pontocerebeloso/patología , Neoplasias Cerebelosas/diagnóstico , Lipoma/diagnóstico , Imagen por Resonancia Magnética , Tomografía Computarizada por Rayos X
20.
Rev. AMRIGS ; 35(2): 74-9, abr.-jun. 1991. tab
Artículo en Portugués | LILACS | ID: lil-99861

RESUMEN

O resultado do tratamento da acromegalia foi avaliado numa serie de 12 pacientes. Em 4 deles foi obtido nivel de GH inferior a 5ng/ml. Este resultado foi alcancado em um caso atraves da cirurgia transesfenoidal e em 3 casos com cirurgia seguida de radioterapia. O seguimentos dos pacientes apos radioterapia ainda permite a obtencao do nivel desejado de GH em maior numero de casos. O resultado aqui obtido esta relacionado a altos niveis de GH na epoca do diagnostico e ao tamanho dos adenomas. Estes dados reforcam a importancia de diagnosticar precocemente esta patologia, para obtencao de melhor resultado terapeutico e diminuicao de sua morbidade


Asunto(s)
Adulto , Humanos , Masculino , Femenino , Acromegalia/radioterapia , Acromegalia/cirugía , Adenoma , Adenohipófisis/patología , Hormona del Crecimiento , Estudios de Seguimiento , Neoplasias Hipofisarias
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA